TMS Co., Ltd【JP:4891】Stock Price

Timbs Inc. is a company with a single business segment: pharmaceutical development, which encompasses research, development, manufacturing, and sales of pharmaceutical products. The company is a drug discovery bioventure firm that conducts research and development of pharmaceutical candidate substances based on outcomes from research institutions such as academia, with a focus on global market expansion.

Timbs is advancing research and development of SMTP compounds, which are pharmaceutical candidate substances targeting soluble epoxide hydrolase (sEH). Inhibiting sEH has been shown to produce anti-inflammatory effects, and the company is developing sEH inhibitors targeting various inflammatory diseases.

Timbs' lead pipeline candidate, TMS-007, possesses both anti-inflammatory effects through sEH inhibition and thrombolytic effects by acting on plasminogen. Clinical development is underway for acute ischemic stroke, while the follow-on pipeline candidate TMS-008 is being developed for various inflammatory disease indications.

The company's pipeline includes TMS-007, TMS-008, and TMS-009, which all belong to the SMTP compound family. SMTP is a group of compounds consisting of a compound produced by a type of black mold and its derivatives, possessing anti-inflammatory effects based on sEH inhibitory activity.

Timbs employs a business model in which it conducts research through early clinical stages in-house, and from late-stage clinical development onward, partners with pharmaceutical companies domestically and internationally by granting development, manufacturing, and commercialization rights. The company generates revenue through upfront payments and royalties from its partners.

Tims Corporation aims to address unmet medical needs through the development of innovative pharmaceuticals. The company focuses on developing novel compounds based on proprietary mechanisms of action, particularly advancing research on anti-inflammatory drugs that work through sEH (soluble epoxide hydrolase) inhibition.

Tims adopts a strategy of simultaneous global market expansion, approaching major markets worldwide. This approach streamlines the recovery of development costs and leverages harmonized international pharmaceutical regulations to accelerate concurrent development in advanced markets.

As part of its growth strategy, the company is advancing pharmaceutical development centered on TMS-007, targeting acute ischemic stroke and acute kidney injury. Additionally, through a partnership with CORXEL, the company is developing JX09, for which it has acquired commercialization rights in Japan.

Tims actively incorporates drug discovery seeds from academia and expands its pipeline to pursue entry into the global pharmaceutical market. Through this approach, the company aims to serve as a bridge between Japanese scientific breakthroughs and the global pharmaceutical industry.

The company adopts a business model that reduces development risk through partnerships with pharmaceutical companies, generating upfront payments and milestone revenues. This approach addresses funding needs as development progresses and strengthens financial stability.

Tims prioritizes securing talented personnel and strengthening its organizational structure. The company promotes organizational development that encourages open discussion across specialized fields and builds teams that leverage expertise in research, manufacturing, regulatory affairs, and development.